See more : GPX Medical AB (publ) (GPXMED.ST) Income Statement Analysis – Financial Results
Complete financial analysis of ACADIA Pharmaceuticals Inc. (ACAD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ACADIA Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Quipt Home Medical Corp. (QIPT) Income Statement Analysis – Financial Results
- China Everbright Greentech Limited (1257.HK) Income Statement Analysis – Financial Results
- ORCHASP LIMITED (ORCHASP.BO) Income Statement Analysis – Financial Results
- PT Astra Agro Lestari Tbk (AAGRY) Income Statement Analysis – Financial Results
- Everfuel A/S (EFUEL.OL) Income Statement Analysis – Financial Results
ACADIA Pharmaceuticals Inc. (ACAD)
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 726.44M | 517.24M | 484.15M | 441.76M | 339.08M | 223.81M | 124.90M | 17.33M | 61.00K | 120.00K | 1.15M | 4.91M | 2.07M | 42.14M | 6.40M | 1.59M | 7.56M | 8.13M | 10.96M | 4.60M | 7.38M | 6.28M | 3.71M | 4.31M |
| Cost of Revenue | 45.73M | 10.17M | 19.14M | 20.55M | 19.60M | 18.33M | 13.06M | 4.41M | 76.37M | 60.60M | 26.72M | 18.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 680.71M | 507.07M | 465.00M | 421.21M | 319.48M | 205.48M | 111.84M | 12.93M | -76.31M | -60.48M | -25.58M | -13.89M | 2.07M | 42.14M | 6.40M | 1.59M | 7.56M | 8.13M | 10.96M | 4.60M | 7.38M | 6.28M | 3.71M | 4.31M |
| Gross Profit Ratio | 93.70% | 98.03% | 96.05% | 95.35% | 94.22% | 91.81% | 89.54% | 74.58% | -125,095.08% | -50,401.67% | -2,233.80% | -283.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 351.62M | 361.58M | 239.42M | 319.13M | 240.39M | 187.16M | 149.19M | 99.28M | 73.87M | 60.60M | 26.72M | 18.79M | 17.31M | 20.58M | 41.59M | 56.75M | 57.94M | 49.40M | 30.85M | 23.45M | 16.94M | 14.92M | 13.09M | 9.73M |
| General & Administrative | 393.07M | 363.59M | 396.03M | 388.66M | 325.64M | 265.76M | 255.06M | 186.46M | 90.80M | 32.75M | 12.72M | 7.00M | 7.61M | 6.46M | 10.28M | 11.82M | 12.27M | 11.35M | 15.91M | 7.25M | 4.18M | 3.98M | 3.76M | 3.00M |
| Selling & Marketing | 9.40M | 5.50M | 41.80M | 51.10M | 38.30M | 39.80M | 15.60M | 1.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 402.47M | 369.09M | 396.03M | 388.66M | 325.64M | 265.76M | 255.06M | 186.46M | 90.80M | 32.75M | 12.72M | 7.00M | 7.61M | 6.46M | 10.28M | 11.82M | 12.27M | 11.35M | 15.91M | 7.25M | 4.18M | 3.98M | 3.76M | 3.00M |
| Other Expenses | 0.00 | 3.54M | 2.33M | -997.00K | 997.00K | -1.84M | 3.98M | 1.33M | 2.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.56M | 7.53M | 2.36M | 0.00 | 0.00 | 2.15M | 2.85M |
| Operating Expenses | 754.09M | 730.67M | 635.44M | 707.79M | 566.02M | 452.92M | 404.25M | 285.74M | 164.67M | 93.35M | 39.44M | 25.79M | 24.92M | 27.04M | 51.87M | 68.57M | 70.21M | 57.19M | 46.76M | 30.70M | 21.12M | 18.90M | 18.99M | 15.58M |
| Cost & Expenses | 799.82M | 740.83M | 654.58M | 728.34M | 585.62M | 471.25M | 417.31M | 290.15M | 164.67M | 93.35M | 39.44M | 25.79M | 24.92M | 27.04M | 51.87M | 68.57M | 70.21M | 57.19M | 46.76M | 30.70M | 21.12M | 18.90M | 18.99M | 15.58M |
| Interest Income | 17.23M | 6.61M | 591.00K | 6.61M | 11.17M | 5.35M | 4.13M | 2.76M | 499.00K | 755.00K | 349.00K | 37.00K | 87.00K | 82.00K | 409.00K | 2.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.00K | 86.00K | 181.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.55M | 2.03M | 3.34M | 2.93M | 2.77M | 3.01M | 2.71M | 1.83M | 647.00K | 206.00K | 79.00K | 109.00K | 285.00K | 607.00K | 1.11M | 1.04M | 768.00K | -146.00K | 1.03M | 1.31M | 1.34M | 1.40M | 0.00 | 0.00 |
| EBITDA | -67.83M | -221.57M | -167.10M | -286.59M | -243.78M | -244.44M | -289.70M | -270.99M | -163.47M | -93.02M | -38.22M | -20.78M | -22.48M | 15.70M | -44.36M | -66.98M | -62.65M | -49.05M | -32.93M | -24.18M | -12.40M | -11.22M | -15.28M | -11.27M |
| EBITDA Ratio | -9.34% | -43.23% | -35.20% | -64.87% | -72.71% | -110.56% | -234.11% | -1,574.14% | -269,855.74% | -77,691.67% | -3,337.82% | -425.64% | -1,091.78% | 37.26% | -693.19% | -4,212.45% | -819.14% | -646.92% | -317.45% | -538.40% | -168.01% | -178.84% | -411.39% | -261.34% |
| Operating Income | -73.38M | -223.60M | -170.44M | -286.59M | -246.55M | -247.44M | -292.41M | -272.82M | -164.61M | -93.23M | -38.30M | -20.89M | -22.85M | 15.09M | -45.47M | -66.98M | -62.65M | -49.05M | -35.81M | -26.10M | -13.74M | -12.63M | -15.28M | -11.27M |
| Operating Income Ratio | -10.10% | -43.23% | -35.20% | -64.87% | -72.71% | -110.56% | -234.11% | -1,574.14% | -269,855.74% | -77,691.67% | -3,344.72% | -425.64% | -1,105.56% | 35.82% | -710.55% | -4,212.45% | -829.31% | -603.15% | -326.81% | -566.76% | -186.22% | -201.19% | -411.39% | -261.34% |
| Total Other Income/Expenses | 22.34M | 10.15M | 2.92M | 5.61M | 12.16M | 3.51M | 4.13M | 2.76M | 499.00K | 755.00K | 349.00K | 37.00K | 87.00K | 45.00K | 323.00K | 2.73M | 6.26M | 3.96M | -4.55M | 178.20K | 0.00 | 0.00 | 15.28M | 11.27M |
| Income Before Tax | -51.04M | -213.44M | -167.52M | -280.97M | -234.38M | -243.94M | -288.28M | -270.05M | -164.11M | -92.48M | -37.95M | -20.85M | -22.77M | 15.14M | -45.15M | -64.24M | -56.39M | -45.05M | -34.14M | -25.92M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -7.03% | -41.27% | -34.60% | -63.60% | -69.12% | -108.99% | -230.81% | -1,558.20% | -269,037.70% | -77,062.50% | -3,314.24% | -424.88% | -1,101.35% | 35.93% | -705.50% | -4,040.50% | -746.39% | -553.89% | -311.56% | -562.89% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 10.25M | 2.53M | 351.00K | 611.00K | 876.00K | 1.26M | 1.12M | 1.34M | 330.00K | -206.00K | 0.00 | -109.00K | 0.00 | 0.00 | 0.00 | -1.04M | 0.00 | -3.86M | -200.00 | -200.00 | 352.60K | 242.30K | 14.41M | 10.19M |
| Net Income | -61.29M | -215.98M | -167.87M | -281.58M | -235.26M | -245.19M | -289.40M | -271.39M | -164.44M | -92.48M | -37.95M | -20.85M | -22.77M | 15.14M | -45.15M | -64.24M | -56.39M | -45.05M | -34.14M | -25.92M | -14.09M | -12.87M | -14.41M | -10.19M |
| Net Income Ratio | -8.44% | -41.76% | -34.67% | -63.74% | -69.38% | -109.56% | -231.71% | -1,565.94% | -269,578.69% | -77,062.50% | -3,314.24% | -424.88% | -1,101.35% | 35.93% | -705.50% | -4,040.50% | -746.39% | -553.89% | -311.56% | -562.89% | -191.00% | -205.05% | -387.88% | -236.41% |
| EPS | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 | -0.38 | -0.44 | 0.39 | -1.20 | -1.73 | -1.60 | -1.61 | -1.55 | -2.50 | -9.66 | -8.86 | -11.93 | -9.53 |
| EPS Diluted | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 | -0.38 | -0.44 | 0.39 | -1.20 | -1.73 | -1.60 | -1.61 | -1.55 | -2.50 | -1.24 | -8.86 | -11.93 | -9.53 |
| Weighted Avg Shares Out | 163.82M | 161.68M | 160.49M | 157.33M | 147.20M | 126.58M | 122.60M | 115.86M | 100.63M | 97.25M | 85.72M | 54.87M | 52.18M | 38.59M | 37.48M | 37.11M | 35.21M | 27.92M | 22.01M | 10.35M | 1.46M | 1.45M | 1.21M | 1.07M |
| Weighted Avg Shares Out (Dil) | 163.82M | 161.68M | 160.49M | 157.33M | 147.20M | 126.58M | 122.60M | 115.86M | 100.63M | 97.25M | 85.72M | 55.12M | 52.18M | 38.72M | 37.48M | 37.11M | 35.21M | 27.92M | 22.01M | 10.35M | 11.37M | 1.45M | 1.21M | 1.07M |
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growth could come from two late-stage assets known...
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. The first indication...
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL 7th Annual Evercore...
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 70,571 shares of common stock and...
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has...
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth
ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
Source: https://incomestatements.info
Category: Stock Reports